Clinical Trials Logo

COVID-19 clinical trials

View clinical trials related to COVID-19.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT04604184 Terminated - COVID-19 Clinical Trials

ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19

Start date: November 3, 2020
Phase: Phase 2
Study type: Interventional

This study is open to adults with COVID-19 infection who are in hospital and receive oxygen. Participants need to be 50 years of age or older and need to be at risk of further worsening of their condition. The purpose of the study is to find out whether a medicine called BI 764198 helps people with COVID-19 infection and breathing problems. BI 764198 may prevent cell death and swelling of the lung tissue and therefore help patients with COVID-19 infection. Participants are put into 2 groups by chance. One group of participants gets BI 764198 capsules and the other group gets placebo capsules. The placebo capsules look exactly like the BI 764198 capsules but do not contain any medicine. Participants take 1 capsule per day. Participants are in the study for about a month. At study end, doctors compare the 2 groups for the number of patients that are alive and do not need mechanical breathing support. During the study, the doctors collect information on any health problems of the participants.

NCT ID: NCT04581070 Terminated - Cancer Clinical Trials

The COVID-IYON Study - Study Examining Data Pertaining to Clinical Outcomes and Organisational Responses to the 2020 SARS-CoV-2 Pandemic"

Start date: April 29, 2020
Phase:
Study type: Observational

This is a prospective, multisite, descriptive, observational clinical/epidemiological study examining both quantitative and qualitative data pertaining to clinical outcomes and organizational responses to the 2020 SARS-Coronavirus-2 (SARS-CoV-2) pandemic.

NCT ID: NCT04504032 Terminated - COVID-19 Clinical Trials

A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)

Start date: September 2, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess safety and clinical efficacy of rivaroxaban in people with mild Coronavirus Disease 2019 who are at increased risk of disease progression.

NCT ID: NCT04497948 Terminated - COVID-19 Clinical Trials

Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19

Start date: September 21, 2020
Phase: Phase 1
Study type: Interventional

Study D822FC00005 will investigate the Phamacokinetics, Safety and tolerability of Acalabrutinib suspension when delivered via a nasogastric tube and co-administered with a Proton Pump Inhibitor, in the treatment of COVID-19.

NCT ID: NCT04435808 Terminated - COVID-19 Clinical Trials

Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19

Start date: April 14, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The HCW Prophylaxis (HCWP) Study, single, open and off label intervention study. Up to 350 participants will be assigned to group that takes HCQ or group that opts to not take study medication. Participants will be UNM HEALTH SYSTEM HCW at high risk for occupational exposure to SARSCoV- 2. Study timepoints will include Day 1 screening/enrollment, 30 day, 60 day, and 90 day assessments. Questionnaires will be collected in all timepoints.

NCT ID: NCT04433546 Terminated - Pneumonia Clinical Trials

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

VANGARD
Start date: July 15, 2020
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of pemziviptadil (PB1046) by improving the clinical outcomes in hospitalized COVID-19 patients at high risk for rapid clinical deterioration, acute respiratory distress syndrome (ARDS) and death. The study will enroll approximately 210 hospitalized COVID-19 patients who require urgent decision-making and treatment at approximately 20 centers in the United States.

NCT ID: NCT04432298 Terminated - COVID-19 Clinical Trials

Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease

Start date: June 20, 2020
Phase: Phase 2
Study type: Interventional

This study evaluates the efficacy and safety of intravenous (IV) infusions of pamrevlumab when compared with placebo in participants who are hospitalized with acute COVID-19 disease.

NCT ID: NCT04410354 Terminated - COVID-19 Clinical Trials

Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19

Start date: June 16, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of merimepodib (MMPD) oral solution when administered in combination with remdesivir in adult patients with advanced COVID-19.

NCT ID: NCT04403646 Terminated - COVID-19 Clinical Trials

Tannin Specific Natural Extract for COVID-19 Infection

TanCOVID
Start date: June 12, 2020
Phase: N/A
Study type: Interventional

There is an urgent need to evaluate interventions that could be effective against the infection with SARS-CoV 2. Tannins based wood extracts are an inexpensive and safe product with protective effect in both bacterial and viral infections likely due to its anti- inflammatory, anti-oxidative effects and their modulation of the intestinal microbiota. This randomized controlled trial seeks to evaluate the efficacy of the tannins based dietary supplement ARBOX in positive COVID-19 patients.

NCT ID: NCT04393155 Terminated - COVID-19 Clinical Trials

COVID Cohort Study

Start date: April 16, 2020
Phase:
Study type: Observational

The novel SARS-CoV-2 virus has quickly spread worldwide, with substantial morbidity and mortality. There is very limited understanding of the short- and longer-term inflammatory/immunological and clinical course. However, the investigators expect survivors from severe COVID-19 to experience persistent functional impairments, as demonstrated in prior studies of patients with acute respiratory distress syndrome (ARDS) and other acute viral illnesses. Notably, however, few studies have ever investigated the biologic mechanisms underlying these functional impairments. Understanding these features of COVID-19 will improve the ability to design acute therapies and recovery-focused interventions. To address these knowledge gaps, the investigators propose a two-center, 225 patient longitudinal prospective cohort study of hospitalized COVID-19 patients with acute respiratory failure. Researchers will perform an in-depth evaluation of inflammatory/immunological biomarkers, and physical, pulmonary, and neuropsychological clinical outcomes during hospitalization, and over 3-, 6-, and 12-month follow-up.